DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,016,858 | +25.2% | 48,436 | +21.1% | 0.36% | +22.1% |
| Q2 2023 | $9,598,725 | +1.3% | 39,995 | +6.4% | 0.29% | -10.6% |
| Q1 2023 | $9,475,479 | -13.1% | 37,595 | -8.5% | 0.33% | -26.9% |
| Q4 2022 | $10,907,169 | +1.3% | 41,094 | -1.4% | 0.45% | -7.6% |
| Q3 2022 | $10,766,000 | +13.3% | 41,684 | +11.2% | 0.49% | +10.7% |
| Q2 2022 | $9,506,000 | +7.0% | 37,498 | +23.8% | 0.44% | +2.3% |
| Q1 2022 | $8,886,000 | +11.7% | 30,293 | +25.3% | 0.43% | -8.3% |
| Q4 2021 | $7,953,000 | +36.9% | 24,173 | +26.6% | 0.47% | -10.2% |
| Q3 2021 | $5,811,000 | +30.5% | 19,087 | +15.1% | 0.52% | +12.0% |
| Q2 2021 | $4,452,000 | +84.5% | 16,588 | +54.7% | 0.47% | +27.7% |
| Q1 2021 | $2,413,000 | +4.1% | 10,722 | +2.8% | 0.36% | -27.6% |
| Q4 2020 | $2,317,000 | +19.9% | 10,431 | +16.2% | 0.50% | -7.0% |
| Q3 2020 | $1,933,000 | +58.6% | 8,975 | +30.1% | 0.54% | -2.0% |
| Q2 2020 | $1,219,000 | +28.6% | 6,896 | +0.7% | 0.55% | 0.0% |
| Q1 2020 | $948,000 | – | 6,851 | – | 0.55% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |